Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease

William Hogan, Rainer Storb

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) currently provides the only chance of curative therapy for many patients with hematological malignancies. Owing to the excess morbidity and mortality observed in less robust patients, this approach has traditionally been limited to younger patients without significant medical co-morbidities. Given the age profiles of patients with candidate hematological malignancies, a majority of patients are therefore ineligible for myeloablative therapy. Over the past few years the ability to achieve hematopoietic stem cell engraftment using immunosuppressive but non-myeloablative conditioning regimens has made it possible to consider a much broader group of patients for allogeneic HSCT. The discovery that the hematopoietic graft itself can contribute to the eradication of malignant cells through a graft-versus-malignancy (GVM) effect, independent of the conditioning regimen, has led to investigation of reduced intensity conditioning regimens for a variety of malignant diseases. Over the past few years there has been a dramatic increase in the number of patients undergoing reduced intensity conditioning for both malignant and nonmalignant conditions. This review will focus only on the use of such therapy for malignant disease.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalImmunologic Research
Volume28
Issue number1
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Therapeutics
Morbidity
Transplants
Immunosuppressive Agents
Hematopoietic Stem Cells
Mortality
Neoplasms

Keywords

  • Hematopoietic
  • Non-myeloablative
  • Stem cell transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. / Hogan, William; Storb, Rainer.

In: Immunologic Research, Vol. 28, No. 1, 2003, p. 1-11.

Research output: Contribution to journalReview article

@article{f43e3f5724a2411bb9aefa61ff4e192c,
title = "Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) currently provides the only chance of curative therapy for many patients with hematological malignancies. Owing to the excess morbidity and mortality observed in less robust patients, this approach has traditionally been limited to younger patients without significant medical co-morbidities. Given the age profiles of patients with candidate hematological malignancies, a majority of patients are therefore ineligible for myeloablative therapy. Over the past few years the ability to achieve hematopoietic stem cell engraftment using immunosuppressive but non-myeloablative conditioning regimens has made it possible to consider a much broader group of patients for allogeneic HSCT. The discovery that the hematopoietic graft itself can contribute to the eradication of malignant cells through a graft-versus-malignancy (GVM) effect, independent of the conditioning regimen, has led to investigation of reduced intensity conditioning regimens for a variety of malignant diseases. Over the past few years there has been a dramatic increase in the number of patients undergoing reduced intensity conditioning for both malignant and nonmalignant conditions. This review will focus only on the use of such therapy for malignant disease.",
keywords = "Hematopoietic, Non-myeloablative, Stem cell transplantation",
author = "William Hogan and Rainer Storb",
year = "2003",
doi = "10.1385/IR:28:1:1",
language = "English (US)",
volume = "28",
pages = "1--11",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease

AU - Hogan, William

AU - Storb, Rainer

PY - 2003

Y1 - 2003

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) currently provides the only chance of curative therapy for many patients with hematological malignancies. Owing to the excess morbidity and mortality observed in less robust patients, this approach has traditionally been limited to younger patients without significant medical co-morbidities. Given the age profiles of patients with candidate hematological malignancies, a majority of patients are therefore ineligible for myeloablative therapy. Over the past few years the ability to achieve hematopoietic stem cell engraftment using immunosuppressive but non-myeloablative conditioning regimens has made it possible to consider a much broader group of patients for allogeneic HSCT. The discovery that the hematopoietic graft itself can contribute to the eradication of malignant cells through a graft-versus-malignancy (GVM) effect, independent of the conditioning regimen, has led to investigation of reduced intensity conditioning regimens for a variety of malignant diseases. Over the past few years there has been a dramatic increase in the number of patients undergoing reduced intensity conditioning for both malignant and nonmalignant conditions. This review will focus only on the use of such therapy for malignant disease.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) currently provides the only chance of curative therapy for many patients with hematological malignancies. Owing to the excess morbidity and mortality observed in less robust patients, this approach has traditionally been limited to younger patients without significant medical co-morbidities. Given the age profiles of patients with candidate hematological malignancies, a majority of patients are therefore ineligible for myeloablative therapy. Over the past few years the ability to achieve hematopoietic stem cell engraftment using immunosuppressive but non-myeloablative conditioning regimens has made it possible to consider a much broader group of patients for allogeneic HSCT. The discovery that the hematopoietic graft itself can contribute to the eradication of malignant cells through a graft-versus-malignancy (GVM) effect, independent of the conditioning regimen, has led to investigation of reduced intensity conditioning regimens for a variety of malignant diseases. Over the past few years there has been a dramatic increase in the number of patients undergoing reduced intensity conditioning for both malignant and nonmalignant conditions. This review will focus only on the use of such therapy for malignant disease.

KW - Hematopoietic

KW - Non-myeloablative

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0042877339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042877339&partnerID=8YFLogxK

U2 - 10.1385/IR:28:1:1

DO - 10.1385/IR:28:1:1

M3 - Review article

VL - 28

SP - 1

EP - 11

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1

ER -